SCHEMBL807454

SCHEMBL807454

CC(C)[C@H]1CNCC1c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 8/20 0.43
KDM1A O60341 7/20 0.43
MAOB P27338 9/20 0.40
CCR5 P51681 1/20 0.40
HTR2C P28335 2/20 0.39
KIF11 P52732 1/20 0.38
BACE1 P56817 1/20 0.38
CYP2C19 P33261 4/20 0.38
CYP2B6 P20813 3/20 0.38
CYP1A2 P05177 2/20 0.38
CYP2D6 P10635 2/20 0.38
CYP2C9 P11712 2/20 0.38
LMNA P02545 2/20 0.38
TAAR1 Q96RJ0 2/20 0.38
CYP3A4 P08684 1/20 0.38
HTR1A P08908 1/20 0.38
ADRA2A P08913 1/20 0.38
CYP2A6 P11509 1/20 0.38
SLC6A2 P23975 1/20 0.38
ADRA1A P35348 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17084154 1.00 MAOA (0.43) MAOAKDM1AMAOBCCR5HTR2C
SCHEMBL17084189 1.00 MAOA (0.43) MAOAKDM1AMAOBCCR5HTR2C
SCHEMBL15081932 1.00 MAOA (0.43) MAOAKDM1AMAOBCCR5HTR2C
SCHEMBL15082019 0.85 SLC6A2 (0.37) MAOAKDM1AHTR2CKIF11CYP2D6
SCHEMBL15081942 0.85 SLC6A2 (0.37) MAOAKDM1AHTR2CKIF11CYP2D6
SCHEMBL807449 0.85 SLC6A2 (0.37) MAOAKDM1AHTR2CKIF11CYP2D6
SCHEMBL15082023 0.83 HTR2C (0.37) HTR2CCYP2C19CYP1A2CYP2C9CYP3A4
SCHEMBL15081930 0.83 HTR2C (0.37) HTR2CCYP2C19CYP1A2CYP2C9CYP3A4
SCHEMBL10210989 0.83 HTR2C (0.37) HTR2CCYP2C19CYP1A2CYP2C9CYP3A4
SCHEMBL31435504 0.81 MAOA (0.43) MAOAKDM1AMAOBCCR5HTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9242981-B2 Fused pyrazole derivatives as novel ERK inhibitors MERCK SHARP & DOHME CORP. (US) 2016-01-26 US disclosed
US-20130172341-A1 FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS MERCK SHARP & DOHME LLC 2013-07-04 US disclosed
WO-2012036997-A1 FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS SCHERING CORPORATION (US) 2012-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130172341-A1 FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS MAPK1, MAPK3, MAP3K1 MAOA 3740/4885KDM1A 3118/4885MAOB 3012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.